Intec Pharma Ltd.

Intec Pharma Ltd.

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill (AP) platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism.
Automation & Control
1d 5d 1m 6m 1y Max

Intec Pharma Ltd. News

25 Jun

Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in

Accordion Pill demonstrated more stable levodopa concentrations and significantly reduced OFF time in Parkinson's disease patients JERUSALEM , June 25, 2019 /PRNewswire/ ---  Intec Pharma Ltd. (NASDAQ:...

19 Jun

Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Wer

JERUSALEM , June 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announced that results from a pharmacokinetics (PK) study of the Accordion ...

28 May

Intec Pharma to Participate at June Investment Conferences

JERUSALEM , May 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming ...

20 May

Intec Pharma Granted European Patent

JERUSALEM, May 20, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that the European Patent Office has granted the Company European Patent No. 2997953 titled, "DELIVERY...

16 May

Intec Pharma Announces Research Collaboration Agreement With Merck

"We are very excited to collaborate with Merck," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "We believe this program, as well as our ongoing collaboration with...

16 May

GEVO, TRQ among premarket gainers

Iovance Biotherapeutics (NASDAQ: IOVA ) +36% on positive TIL data . More news on: Iovance Biotherapeutics, Inc., CUI Global, Inc., MacroGenics, Inc., Stocks on the move, Read more …

07 May

Intec Pharma beats by $0.05

Intec Pharma (NASDAQ: NTEC ): Q1 GAAP EPS of -$0.32 beats by $0.05. More news on: Intec Pharma Ltd., Earnings news and commentary, Healthcare stocks news, , Read more …

07 May

Intec Pharma Reports First Quarter 2019 Financial Results and Corporate Update

JERUSALEM , May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three months ended March 31, 2019 and provides a corporate...

02 May

Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for P

JERUSALEM , May 2, 2019 /PRNewswire/  -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the results from a pharmacokinetics (PK) study of the Accordion ...

30 Apr

Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa

Company on track to report top-line data in July/August time frame JERUSALEM , April 30, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces ...

Load more

About Intec Pharma Ltd.

Intec’s strategy is to leverage its proprietary delivery technology to improve the properties of known/approved compounds, with plans to partner these for full development and commercialization. Intec also plans to work in collaboration with biotechnology and pharmaceutical companies to develop novel delivery systems for their proprietary drugs, including existing compounds undergoing lifecycle management.

The Company’s product pipeline includes two candidates in clinical development:

- Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is currently in a pivotal Phase 3 trial for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, and
- AP-cannabinoids, early stage development of a system to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various indications including low back pain, neuropathic pain and fibromyalgia.

Team

Jeffrey A. Meckler
CEO and Vice Chairman of the Board
Nadav Navon
Chief Operating Officer
Nir Sassi
Chief Financial Officer
R. Michael Gendreau
Chief Medical Officer
Walt A. Linscott
Chief Business Officer
John W. Kozarich
Chairman of the Board
$ 0.51
-3.05%
Open:
0.55
High:
0.57
Low:
0.50
Market cap:
157.164 M
Symbol:
NTEC

Services

Delivery

Yes